Manifaxine

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Manifaxine
Manifaxine.svg
Systematic (IUPAC) name
(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol
Identifiers
CAS Number 135306-39-7 YesY
ATC code none
PubChem CID: 60829
ChemSpider 54816 N
UNII J8IE53G2IV YesY
Chemical data
Formula C12H15F2NO2
Molecular mass 243.249 g/mol
  • C[C@@H]1CO[C@]([C@@H](N1)C)(C2=CC(=CC(=C2)F)F)O
  • InChI=1S/C12H15F2NO2/c1-7-6-17-12(16,8(2)15-7)9-3-10(13)5-11(14)4-9/h3-5,7-8,15-16H,6H2,1-2H3/t7-,8+,12-/m1/s1 N
  • Key:OZGPVYJHWWPEFT-RGNHYFCHSA-N N
 NYesY (what is this?)  (verify)

Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, one of the major active metabolites[citation needed] of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications,[1][2] but no results have been reported following these initial trials and its current status is unclear.

See also

References

  1. DeVeaugh-Geiss J, Conners CK, Sarkis EH, Winner PK, Ginsberg LD, Hemphill JM, Laurenza A, Barrows CE, Webster CJ, Stotka CJ, Asgharnejad M. GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. Journal of the American Academy of Child and Adolescent Psychiatry. 2002 Aug;41(8):914-20. PMID 12162627
  2. Spraggs CF, Pillai SG, Dow D, Douglas C, McCarthy L, Manasco PK, Stubbins M, Roses AD. Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenetics and Genomics. 2005 Dec;15(12):883-9. PMID 16272960


<templatestyles src="Asbox/styles.css"></templatestyles>